These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 7853170)

  • 1. Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects.
    Mumford GK; Rush CR; Griffiths RR
    J Pharmacol Exp Ther; 1995 Feb; 272(2):570-80. PubMed ID: 7853170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tandospirone and alprazolam: comparison of behavioral effects and abuse liability in humans.
    Evans SM; Troisi JR; Griffiths RR
    J Pharmacol Exp Ther; 1994 Nov; 271(2):683-94. PubMed ID: 7965783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alprazolam absorption kinetics affects abuse liability.
    Mumford GK; Evans SM; Fleishaker JC; Griffiths RR
    Clin Pharmacol Ther; 1995 Mar; 57(3):356-65. PubMed ID: 7697954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability.
    Evans SM; Funderburk FR; Griffiths RR
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1246-55. PubMed ID: 2262904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group.
    Lydiard RB; Ballenger JC; Rickels K
    J Clin Psychiatry; 1997; 58 Suppl 11():11-8. PubMed ID: 9363043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral effects of alprazolam in humans.
    Kelly TH; Foltin RW; Serpick E; Fischman MW
    Behav Pharmacol; 1997 Feb; 8(1):47-57. PubMed ID: 9833000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral and subjective effects of DN-2327 (pazinaclone) and alprazolam in normal volunteers.
    Evans SM; Foltin RW; Levin FR; Fischman MW
    Behav Pharmacol; 1995 Mar; 6(2):176-186. PubMed ID: 11224325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of alprazolam on the baseline and fear-potentiated startle reflex in humans: a dose-response study.
    Riba J; Rodríguez-Fornells A; Urbano G; Morte A; Antonijoan R; Barbanoj MJ
    Psychopharmacology (Berl); 2001 Oct; 157(4):358-67. PubMed ID: 11605094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lorazepam and meprobamate dose effects in humans: behavioral effects and abuse liability.
    Roache JD; Griffiths RR
    J Pharmacol Exp Ther; 1987 Dec; 243(3):978-88. PubMed ID: 3694540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subjective and physiological effects of intravenous nicotine and cocaine in cigarette smoking cocaine abusers.
    Jones HE; Garrett BE; Griffiths RR
    J Pharmacol Exp Ther; 1999 Jan; 288(1):188-97. PubMed ID: 9862770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
    Johnson MW; Suess PE; Griffiths RR
    Arch Gen Psychiatry; 2006 Oct; 63(10):1149-57. PubMed ID: 17015817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind, placebo-controlled trial of two doses of abecarnil for geriatric anxiety.
    Small GW; Bystritsky A
    J Clin Psychiatry; 1997; 58 Suppl 11():24-9. PubMed ID: 9363045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative abuse liability of indiplon and triazolam in humans: a comparison of psychomotor, subjective, and cognitive effects.
    Carter LP; Griffiths RR; Suess PE; Casada JH; Wallace CL; Roache JD
    J Pharmacol Exp Ther; 2007 Aug; 322(2):749-59. PubMed ID: 17502431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone.
    Pollack MH; Worthington JJ; Manfro GG; Otto MW; Zucker BG
    J Clin Psychiatry; 1997; 58 Suppl 11():19-23. PubMed ID: 9363044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buspirone and lorazepam abuse liability in humans: behavioral effects, subjective effects and choice.
    Troisi 2nd JR; Critchfield TS; Griffiths RR
    Behav Pharmacol; 1993 Jun; 4(3):217-230. PubMed ID: 11224189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist abecarnil (ZK 112-119) in generalized anxiety disorder.
    Ballenger JC; McDonald S; Noyes R; Rickels K; Sussman N; Woods S; Patin J; Singer J
    Psychopharmacol Bull; 1991; 27(2):171-9. PubMed ID: 1681563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, anticonvulsant efficacy and adverse effects of the beta-carboline abecarnil, a novel ligand for benzodiazepine receptors, after acute and chronic administration in dogs.
    Löscher W; Hönack D; Scherkl R; Hashem A; Frey HH
    J Pharmacol Exp Ther; 1990 Nov; 255(2):541-8. PubMed ID: 1978730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The cognitive effect of alprazolam in healthy volunteers].
    Drabant S; Tömlo J; Tóth M; Péterfai E; Klebovich I
    Acta Pharm Hung; 2006; 76(1):25-31. PubMed ID: 17094673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral caffeine maintenance potentiates the reinforcing and stimulant subjective effects of intravenous nicotine in cigarette smokers.
    Jones HE; Griffiths RR
    Psychopharmacology (Berl); 2003 Jan; 165(3):280-90. PubMed ID: 12434259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human studies on abecarnil a new beta-carboline anxiolytic: safety, tolerability and preliminary pharmacological profile.
    Duka T; Schütt B; Krause W; Dorow R; McDonald S; Fichte K
    Br J Clin Pharmacol; 1993 Apr; 35(4):386-94. PubMed ID: 8097921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.